Is Lantheus Holdings (NASDAQ:LNTH) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will

Simply Wall StJul 2 21:00

Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating

Truist Financial analyst Richard Newitter maintains $Lantheus(LNTH.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.5% and a total average return of 15.5% over t

Futu NewsJun 28 19:33 · Ratings

JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $128

JonesTrading analyst Justin Walsh maintains $Lantheus(LNTH.US)$ with a buy rating, and maintains the target price at $128.According to TipRanks data, the analyst has a success rate of 32.9% and a tota

Futu NewsJun 28 00:31 · Ratings

Unusual Options Activity: CVS, DKNG and Others Attract Market Bets, CVS V/OI Ratio Reaches 137.5

EST Jun 27th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.

Futu NewsJun 27 23:30

Lantheus Holdings Acquires Global Rights to Life Molecular Imaging's RM2

Lantheus Holdings (LNTH) said Thursday that it is acquiring global rights of Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor for prostate and breast cancers. The company

MT NewswiresJun 27 20:05

Lantheus Expands Cancer Pipeline With $35M Acquisition of RM2 Rights

Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcome

BenzingaJun 27 19:10